CHA News

DEA Moves Cannabis-Derived Drug From Schedule I to Schedule V

This post has been archived and contains information that may be out of date.

The Drug Enforcement Administration has moved Epidiolex from Schedule I to Schedule V. According to All Facilities Letter 19-06, issued last week by the California Department of Public Health, cannabis-derived drugs that are approved by the Food and Drug Administration and that have no more than 0.1 percent residual tetrahydrocannabinols will be moved to Schedule V. Currently, only Epidiolex meets those requirements. Drugs that do not meet these criteria may not be prescribed or dispensed.